定量超声评估代谢功能障碍相关脂肪性肝病:国际前瞻性研究
该前瞻性研究纳入中国和韩国三级医院的114例MASLD参与者,评估组织衰减成像(TAI)、组织散射分布成像(TSI)和二维剪切波弹性成像(SWE)对MASLD和MASH的诊断性能。以组织病理学为参考,TAI和TSI对脂肪变分级、SWE对纤维化分期均表现出良好至优秀性能,TSI联合SWE模型对MASH和高危MASH具有良好鉴别能力。
要点
- TAI和TSI评估脂肪变≥S1、≥S2、S3的AUC分别为0.90、0.93、0.78和0.94、0.89、0.80。
- SWE评估纤维化≥F1、≥F2、≥F3、F4的AUC分别为0.81、0.96、0.89、0.97。
- TSI联合SWE模型对MASH的AUC为0.92,对高危MASH的AUC为0.82。
核心结论
- TAI、TSI和SWE有助于准确评估MASLD,TSI联合SWE对预测MASH和高危MASH表现出良好的鉴别能力。
研究设计与样本
- 前瞻性研究,纳入中国和韩国三级医院的114例MASLD参与者,中位年龄40岁(IQR 31-50岁),67例女性,行多参数超声检查,以组织病理学分析为参考标准。
诊断标准与关键数值
- TAI评估脂肪变≥S1、≥S2、S3的AUC分别为0.90、0.93、0.78;TSI分别为0.94、0.89、0.80。
- TSI评估炎症分级≥I1的AUC为0.84(95%CI 0.75, 0.92),敏感度79%,特异度79%。
- SWE评估纤维化≥F1、≥F2、≥F3、F4的AUC分别为0.81、0.96、0.89、0.97,敏感度分别为75%、90%、87%、100%,特异度分别为80%、93%、83%、96%。
- TSI联合SWE模型对MASH的AUC为0.92(95%CI 0.85, 0.98),对高危MASH的AUC为0.82(95%CI 0.74, 0.90)。
- TSI联合SWE模型对MASH的AUC与TSI相比P=.72,对高危MASH的AUC与TSI相比P=.002;对MASH的AUC与SWE相比P<.001,对高危MASH的AUC与SWE相比P=.31。
临床应用与阅片要点
- 本研究表明TAI和TSI可用于无创评估肝脂肪变分级,SWE可用于评估肝纤维化分期。
- TSI联合SWE模型对MASH和高危MASH的鉴别能力优于单独使用TSI或SWE的部分比较。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Quantitative US is promising in assessing metabolic dysfunction-associated steatotic liver disease (MASLD), but prospective multicenter studies are lacking. Purpose To evaluate the diagnostic performance of quantitative US in assessing MASLD and metabolic dysfunction-associated steatohepatitis (MASH). Materials and Methods This prospective study included participants with MASLD from tertiary hospitals in China and Korea, undergoing multiparametric US from August 2021 to December 2023. Diagnostic performance of tissue attenuation imaging (TAI), tissue scatter-distribution imaging (TSI), and two-dimensional shear-wave elastography (SWE) parameters for assessment of MASLD and MASH was evaluated using area under the receiver operating characteristic curve (AUC) analysis, with histopathologic analysis as a reference. Univariable and multivariable analyses identified clinical factors associated with each US parameter. Results A total of 114 participants (median age, 40 years; IQR, 31-50 years; 67 female participants) were evaluated, 76 participants (67%) with MASH and 39 participants (34%) with high-risk MASH (fibrosis score ≥F2). Multivariable analysis indicated TAI and TSI were independently associated with steatosis and SWE was independently associated with fibrosis (all P < .001). TAI and TSI showed excellent performance for assessing steatosis grades S1 or higher, S2 or higher, and S3 (AUCs for TAI: 0.90, 0.93, and 0.78, respectively; AUCs for TSI, 0.94, 0.89, and 0.80, respectively), with TSI demonstrating good performance for inflammation grade I1 or more (AUC, 0.84; 95% CI: 0.75, 0.92; sensitivity, 79%; specificity, 79%). SWE exhibited excellent performance for staging fibrosis scores of F1 or higher, F2 or higher, F3 or higher, and F4 (AUCs: 0.81, 0.96, 0.89, and 0.97, respectively; sensitivities: 75%, 90%, 87%, and 100%, respectively; specificities: 80%, 93%, 83%, and 96%, respectively). The combined TSI and SWE model showed diagnostic advantages for MASH (AUC, 0.92; 95% CI: 0.85, 0.98) and high-risk MASH (AUC, 0.82; 95% CI: 0.74, 0.90) compared with TSI (P = .72 for MASH; P = .002 for high-risk MASH) and SWE (P < .001 for MASH; P = .31 for high-risk MASH). Conclusion TAI, TSI, and SWE helped provide accurate assessment of MASLD, and combining TSI and SWE showed good discrimination for predicting MASH and high-risk MASH. ClinicalTrials.gov Identifier: NCT04985188 © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Dighe and Dhyani in this issue.
引用
- Huang TY, Li ZY, Tian J, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease at Quantitative US: International Prospective Study. Radiology. 2025. PMID: 40662970. doi:10.1148/radiol.242564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。